Environmental exposure of primary care personnel to ribavirin aerosol when supervising treatment of infants with respiratory syncytial virus infections
- 1 July 1987
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 31 (7) , 1143-1146
- https://doi.org/10.1128/aac.31.7.1143
Abstract
The potential exposure to ribavirin aerosol in the environment was assessed in nurses caring for infants and children with severe lower respiratory tract infections due to respiratory syncytial virus. Ribavirin aerosol was administered via a ventilator, oxygen tent, or oxygen hood. Participants worked directly with infants receiving ribavirin for 20.0 to 35.0 h over a 3-day period. No toxic or adverse effects of ribavirin aerosol were observed in any of the 19 nurses studied, and ribavirin was not detected in erythrocytes, plasma, or urine collected after the potential exposure period.This publication has 6 references indexed in Scilit:
- Aerosolized ribavirin in the treatment of patients with respiratory syncytial virus diseaseThe Pediatric Infectious Disease Journal, 1987
- Ribavirin: A clinical overviewEuropean Journal of Epidemiology, 1986
- Ribavirin treatment of respiratory syncytial viral infection in infants with underlying cardiopulmonary diseaseJAMA, 1985
- Ribavirin small-particle aerosol treatment of infections caused by influenza virus strains A/Victoria/7/83 (H1N1) and B/Texas/1/84Antimicrobial Agents and Chemotherapy, 1985
- Sensitive radioimmunoassay for the broad-spectrum antiviral agent ribavirinAntimicrobial Agents and Chemotherapy, 1983
- If nothing goes wrong, is everything all right? Interpreting zero numerators.1983